- Sector: Healthcare
- Industry: Biotechnology
- Full Time Employees: 128
- Founded by Timothy A. Springer and Leonard I. Zon in 2012
- Headquartered in Cambridge, Massachusetts.
- https://www.scholarrock.com
The company announced the results of its earnings performance in the third quarter of the year, where it widened its net loss by 58 percent to $102 million
from $64.5 million in the same period last year, pulled down by a 60
percent higher operating loss of $103.5 million versus $64.78 million
year-on-year.
Scholar Rock investor sentiment was boosted by the progress of its drug candidate for spinal muscular atrophy (SMA).
In
an updated report, Scholar Rock Holding Corp. (NASDAQ:SRRK) said that
it completed “constructive and collaborative” in-person meeting with the
Food and Drug Administration last Wednesday, November 12, for its
biologics license application of apitegromab.
Scholar Rock Holding Corp. said BLA resubmission and US launch is anticipated by next year.
Additionally,
it said that it targets to secure the approval of the European
Medicines Agency (EMA) to sell apitegromab to Europe by mid 2026.
